Dividend approval
Press release FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Eric Nys, general manager, eric.nys@financiere-tubize.be Dividend...
Month: April 2023
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present...
Acutus Medical to Announce First Quarter 2023 Financial Results
CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on...
Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders
TORONTO, April 28, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold...
ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform...
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
Conference call to be held Monday, May 1, 2023, at 8:30 AM ETNEW YORK, April 28, 2023 (GLOBE NEWSWIRE) --...
Preliminary Results for the Year Ended 31 December 2022
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the...
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Artella Solutions, Inc. Announces Expansion into 6 States with New Leadership Team
Growing innovative mobile cardiac telemetry company generating buzz outside of Texas to meet the diagnostic needs of providers to easily...
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics,...
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
GeneDx Announces Reverse Stock Split
STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic...
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary...
Vistant Named by Financial Times as One of the Americas’ Fastest-Growing Companies Once Again
Vistant Remains in the Top 25 Percent Out of 500 CompaniesTOWSON, Md., April 27, 2023 (GLOBE NEWSWIRE) -- Vistant, a...
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001...
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation...
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April...
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., April 27, 2023 (GLOBE...
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...